Mesenchymal Stem/Stromal Cells: CLINICAL-GRADE HUMAN SYNOVIAL FLUID-DERIVED MESENCHYMAL STEM CELLS FOR DEGENERATIVE MENISCUS THERAPY

Uysal O., Avci H., Bagis S., Sevimli T. S., Ozel C., Cevizlidere B. D., ...More

CYTOTHERAPY, vol.25, no.6, pp.92, 2023 (SCI-Expanded, Scopus) identifier

  • Publication Type: Article / Abstract
  • Volume: 25 Issue: 6
  • Publication Date: 2023
  • Doi Number: 10.1016/s1465-3249(23)00296-7
  • Journal Name: CYTOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, MEDLINE
  • Page Numbers: pp.92
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

When meniscal tissue is damaged, there is no gold standard medication and/or surgical treatment that can regenerate the damaged tissue. Currently, although the most effective treatment approach is the surgical method-partial meniscectomy, it provides only symptomatic improvement. The aim of this study is to develop the stem cell treatment protocol in addition/alternative to the surgical method adapt it to the clinical practices, suitable for use in human treatment. For this purpose, all steps of the production process as a Good Manufacturing Practices (GMP)-grade cellular therapy product from the collection of the synovial fluid sample from the patient until the release of the final product; the standard operation procedure of the production was prepared according to the legal regulations.